NRX Therapeutics
NRXP3.2907.06% ( -0.250 )
NRX Therapeutics (NRXP)
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising su...
- Open
- 3.480
- High
- 3.560
- Low
- 3.280
- Prev. Close
- 3.540
- Volume
- 312.75K
- Turnover
- 1.06M
- Avg Price
- 3.391
- Bid/Ask Ratio
- --
- Amplitude
- 7.91%
- 52wk High
- 5.055
- Volume Ratio
- 0.96
- Turnover Ratio
- 1.29%
NRX Therapeutics Analyst Rating
View MoreForecast & Rating
Jun 22, 2026Price forecast
$42.001176.60%
Forecast & RatingStrong buy
4analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Jul 22 at 06:30 AM
NRx Defense Systems Advances DARPA-Backed Depression Trial
- PUBT · Jun 25 at 03:01 PM
NRx Pharmaceuticals pushes Kadima dispute into arbitration amid acquisition lawsuit
- Tip Ranks · Jun 25 at 07:36 AM
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)
- PUBT · Jun 25 at 06:02 AM
NRx subsidiary HOPE Therapeutics begins patient treatments using Zeta Surgical TMS navigation system
- PUBT · Jun 23 at 10:05 AM
HOPE Therapeutics treats first patient using Zeta TMS Navigation System
- rttnews · Jun 22 at 06:52 AM
NRx Pharmaceuticals's NRX-101 Wins FDA Approval For Intermediate Population Expanded Access Protocol
